Management Of Patients With Metastatic Castration-Resistant Prostate Cancer - First-Line Treatment Options According To The Polish National Health Found Therapeutic Program

Prostate cancer is one of the most common malignancies among men worldwide. According to ESMO recommendations, systemic treatment of castrate-resistant prostate cancer (CRPC) patients includes hormonal treatment, radionuclides, and immunotherapy, and the choice of appropriate method depends, among others, on clinical symptoms of disease and possible presence of distant metastases. Polish recommendations regarding systemic treatment of CRPC are different, mainly due to the distinct reimbursement conditions for individual drugs. The purpose of the subsequent two publications is to present the options of systemic treatment for CRPC patients within the Polish National Health Fund drug program. The first of the articles presents first-line treatment.